[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heathly-volunteers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heathly-volunteers":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100645369","phase-2-role-of-a-mitochondrial-receptor-in-blood-sugar-regulation-100645369",false,"NCT07682233","Role of a Mitochondrial Receptor in Blood Sugar Regulation","An Experimental Medicine Study to Investigate the Role of the 18 kiloDalton Translocator Protein in Glucose Metabolism","G-TSPO","Inclusion Criteria:\n\n* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n* Aged 18-75 years old\n* A female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day) and willing to use one of the contraception methods.\n* Male subject must agree to use one of the contraception methods.\n* No history of diabetes.\n\nExclusion Criteria:\n\n* Clinically meaningful abnormalities in routine bloods including:\n\n  * eGFR \\\u003C 60ml\u002Fmin\n  * Elevation of liver enzymes\u002Fbilirubin\n  * Prolonged prothrombin time\n  * Thrombocytopenia\n* Use of the following medications or therapies:\n\n  * P450 CY3A4 inhibitors\n\n    * Potent: Boceprevir, Clarithromycin, Cobicistat, Idelalisib, Itraconazole, Ketoconazole, Nelfinavir, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazoleb\n    * Moderate: Aprepitant, Conivaptan, Crizotinib, Diltiazem, Dronedarone, Erythromycin, Fluconazole, Imatinib, Isavuconazole, Nefazodone, Netupitant, Nilotinib, Posaconazolee, Tofisopam, Verapamil\n    * Unclassified: Delavirdine\n  * P450 CY3A4 inducers\n\n    * Potent: Carbamazepine, Enzalutamide, Fosphenytoin, Mitotane, Phenytoin, Rifampicin\n    * Moderate; Bosentan, Efavirenz, St John's wort\n    * Unclassified; Barbiturates, Nevirapine, Primidone, Rifabutin, Rifapentine\n  * oral contraceptives\n  * oral anticoagulants or antiplatelet agents other than low dose aspirin\n  * levothyroxine\n* Currently breastfeeding.\n* Any clinical significant medical conditions that in the opinion of the investigator would compromise subjects' safety or compliance with study procedures.\n* History of any clinical condition which in the opinion of the principal investigator would compromise the scientific integrity of the study, such as some chronic systemic diseases affecting blood, liver or kidneys or endocrine system.\n* Unwillingness or inability to follow the procedures outlined in the protocol.\n* Subject is mentally or legally incapacitated.\n* Contraindication to XBD173 use:\n\n  * Hypersensitivity to the active substance or to any of the excipients",true,"ALL","18 Years","75 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this clinical trial is to learn whether a single dose of XBD173, a medicine that binds to a protein called the 18 kiloDalton Translocator Protein (TSPO), affects how the body processes glucose in healthy volunteers aged 18 to 75 years.\n\nThe main questions it aims to answer are:\n\n* Does a single dose of XBD173 change fasting blood glucose levels compared with placebo?\n* Does a single dose of XBD173 change blood glucose levels after participants drink a glucose solution compared with placebo?\n\nResearchers will compare XBD173 with a placebo, which does not contain the active medicine, to see whether activating TSPO affects glucose metabolism in the fasting state and after a glucose drink.\n\nParticipants will:\n\n* Attend a screening visit to confirm eligibility, including a medical history, physical examination and blood tests.\n* Attend four study visits after fasting overnight: two visits involving a glucose drink and two visits without a glucose drink.\n* Receive a single oral dose of XBD173 at some visits and placebo at other visits. The order will be randomised, and neither participants nor the study team conducting the assessments will know which treatment is given during each visit.\n* Have repeated blood samples taken through a cannula to measure glucose, insulin and other markers related to metabolism and inflammation.\n* Have resting energy use measured by breathing under a transparent canopy connected to a standard metabolic measurement device.\n* Have blood pressure, heart rate, height and weight measured.\n* Undergo measurement of blood vessel function using a cuff.",[29],"Heathly Volunteers",[31,32,33,34,35,36,37,38,39,40,41,42,43,44],"TSPO","18 kDa Translocator Protein","XBD173","Glucose Metabolism","Fasting Plasma Glucose","Oral Glucose Tolerance Test","OGTT","Insulin Response","Resting Energy Expenditure","Respiratory Quotient","Healthy Volunteers","Randomised Controlled Trials","Randomised Crossover Study","Placebo-Controlled Trial","RECRUITING","2026-06-26",{"date":48,"type":49},"2026-07-02","ACTUAL",{"date":51,"type":49},"2026-03-27",{"date":53,"type":23},"2028-09-01",{"name":55,"class":56},"Imperial College London","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":24,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":5},"100637083","pi-ysp-0111-formulation-on-human-gut-microbiota-and-body-composition-100637083","NCT07618000","PI-YSP-0111 Formulation on Human Gut Microbiota and Body Composition","Evaluation of the Effects of the PI-YSP-0111 Formulation on Human Gut Microbiota and Body Composition","Inclusion Criteria:\n\n1. Healthy males or females aged 18 to 65 years.\n2. BMI between 23.0 and 40.0 kg\u002Fm².\n3. Waist circumference: ≥ 90 cm for males and ≥ 80 cm for females.\n4. Participants are willing to maintain their usual dietary habits, daily routines, and physical activity levels during the study period, and have no plans to relocate.\n5. Participants have fully understood the study procedures and have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of gastrointestinal diseases, such as inflammatory bowel disease, irritable bowel syndrome, gastroesophageal reflux disease, Crohn's disease, or a history of bariatric surgery.\n2. Recent history of acute gastroenteritis, constipation or diarrhea; psychiatric disorders (e.g., depression or schizophrenia); cardiovascular diseases (e.g., hypertension); known allergy or hypersensitivity to the investigational product; extreme dietary habits; significant body weight change (\\>4.5 kg) within the past three months; recent use of antibiotics or antifungal agents; or use of medications affecting gastrointestinal function (such as probiotics, laxatives, or nonsteroidal anti-inflammatory drugs \\[NSAIDs\\]).\n3. Exposure to unapproved medications, alcohol abuse, or substance abuse.\n4. Female-specific conditions, including significant gastrointestinal symptoms during menstruation, irregular menstrual cycles, pregnancy, planned pregnancy, or breastfeeding (participants who become pregnant during the study period will also be excluded).\n5. Short-term use of corticosteroids, nonsteroidal anti-inflammatory drugs, immunosuppressive agents, interferons, or immunomodulatory agents within the past one month.\n6. Use of any weight-loss medications (including oral agents, injections, or traditional Chinese medicine) within the past three months.\n7. Participation in any other interventional clinical study within the past one month.\n8. History of cancer or current malignancy within the past two years, except for non-melanoma skin cancer.\n9. Occurrence of major trauma or any surgical procedures within the past one month.\n10. History of diabetic ketoacidosis.","65 Years",{"count":67,"type":23},140,[69],"NA","The expected outcome of this study is that continuous 8-week supplementation with the PI-YSP-0111 prebiotic formulation will exert beneficial effects on gut microbiota modulation and liver health.",[29],"2026-05-26",{"date":74,"type":49},"2026-06-01",{"date":76,"type":49},"2026-04-08",{"date":78,"type":23},"2027-04-07",{"name":80,"class":56},"Taipei Medical University"]